Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026

A time prior, connected December 17, Canaccord raised the firm’s terms people connected Insulet to $450 from $432 with a Buy standing connected the shares. This was announced arsenic Canaccord reaffirmed its bullish stance connected the MedTech assemblage for 2026. The firm’s affirmative outlook is built connected respective cardinal pillars: accordant request from an aging demographic, a heightened absorption connected acute healthcare requirements, a robust M&A environment, and a marketplace progressively unfastened to caller IPOs. The steadfast peculiarly highlighted Insulet arsenic a apical prime and asserted that the institution is primed for a multi-year rhythm of outperformance owed to the caller statement enlargement and the commercialized rollout of Automated Insulin Delivery systems to the Type 2 diabetes diligent population.

Earlier connected December 16, Evercore ISI initiated sum of Insulet with an Outperform standing and $370 terms target. Despite the accomplishment of caller competitors, the steadfast believes that Insulet’s unsocial tubeless plan is efficaciously revolutionizing the insulin pump marketplace and fueling important growth.

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin transportation systems for radical with insulin-dependent diabetes successful the US and internationally.

While we admit the imaginable of PODD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.